======= PSMA5 =======
== Gene Information ==
* **Official Symbol**: PSMA5
* **Official Name**: proteasome 20S subunit alpha 5
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=5686|5686]]
* **UniProt**: [[https://www.uniprot.org/uniprot/P28066|P28066]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=PSMA5&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PSMA5|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/176844|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). {ECO:0000269|PubMed:15244466, ECO:0000269|PubMed:27176742, ECO:0000269|PubMed:8610016}.
|Proteasome|
|Proteasome A N|
|proteasome core complex, alpha-subunit complex|
|threonine-type endopeptidase activity|
|proteasome core complex|
|proteasomal ubiquitin-independent protein catabolic process|
|proteasome complex|
|regulation of cellular amino acid metabolic process|
|regulation of hematopoietic stem cell differentiation|
|antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent|
|endopeptidase activity|
|regulation of transcription from RNA polymerase II promoter in response to hypoxia|
|antigen processing and presentation of exogenous peptide antigen via MHC class I|
|NIK/NF-kappaB signaling|
|regulation of cellular amine metabolic process|
|anaphase-promoting complex-dependent catabolic process|
|regulation of hematopoietic progenitor cell differentiation|
|negative regulation of G2/M transition of mitotic cell cycle|
|SCF-dependent proteasomal ubiquitin-dependent protein catabolic process|
|interleukin-1-mediated signaling pathway|
|Wnt signaling pathway, planar cell polarity pathway|
|antigen processing and presentation of peptide antigen via MHC class I|
|negative regulation of cell cycle G2/M phase transition|
|regulation of establishment of planar polarity|
|stimulatory C-type lectin receptor signaling pathway|
|secretory granule lumen|
|innate immune response activating cell surface receptor signaling pathway|
|regulation of stem cell differentiation|
|tumor necrosis factor-mediated signaling pathway|
|regulation of transcription from RNA polymerase II promoter in response to stress|
|ficolin-1-rich granule lumen|
|regulation of DNA-templated transcription in response to stress|
|non-canonical Wnt signaling pathway|
|positive regulation of canonical Wnt signaling pathway|
|regulation of cellular ketone metabolic process|
|Fc-epsilon receptor signaling pathway|
|cellular response to interleukin-1|
|negative regulation of canonical Wnt signaling pathway|
|T cell receptor signaling pathway|
|antigen processing and presentation of exogenous peptide antigen|
|positive regulation of Wnt signaling pathway|
|regulation of mRNA stability|
|regulation of morphogenesis of an epithelium|
|antigen processing and presentation of exogenous antigen|
|regulation of RNA stability|
|cellular response to hypoxia|
|antigen processing and presentation of peptide antigen|
|regulation of G2/M transition of mitotic cell cycle|
|cellular response to decreased oxygen levels|
|response to interleukin-1|
|regulation of mRNA catabolic process|
|negative regulation of Wnt signaling pathway|
|regulation of cell cycle G2/M phase transition|
|negative regulation of mitotic cell cycle phase transition|
|cellular response to oxygen levels|
|antigen processing and presentation|
|negative regulation of cell cycle phase transition|
|innate immune response-activating signal transduction|
|cellular response to tumor necrosis factor|
|Fc receptor signaling pathway|
|regulation of animal organ morphogenesis|
|activation of innate immune response|
|response to tumor necrosis factor|
|protein deubiquitination|
|regulation of canonical Wnt signaling pathway|
|antigen receptor-mediated signaling pathway|
|protein modification by small protein removal|
|protein polyubiquitination|
|negative regulation of mitotic cell cycle|
|proteasome-mediated ubiquitin-dependent protein catabolic process|
|negative regulation of cell cycle process|
|regulation of mRNA metabolic process|
|positive regulation of innate immune response|
|response to hypoxia|
|proteasomal protein catabolic process|
|Wnt signaling pathway|
|cell-cell signaling by wnt|
|response to decreased oxygen levels|
|regulation of Wnt signaling pathway|
|post-translational protein modification|
|positive regulation of response to biotic stimulus|
|MAPK cascade|
|response to oxygen levels|
|signal transduction by protein phosphorylation|
|regulation of mitotic cell cycle phase transition|
|cell surface receptor signaling pathway involved in cell-cell signaling|
|regulation of small molecule metabolic process|
|regulation of cell cycle phase transition|
|immune response-activating cell surface receptor signaling pathway|
|regulation of hemopoiesis|
|regulation of innate immune response|
|positive regulation of defense response|
|immune response-regulating cell surface receptor signaling pathway|
|neutrophil degranulation|
|neutrophil activation involved in immune response|
|neutrophil mediated immunity|
|neutrophil activation|
|granulocyte activation|
|positive regulation of multi-organism process|
|leukocyte degranulation|
|myeloid leukocyte mediated immunity|
|myeloid cell activation involved in immune response|
|regulation of response to biotic stimulus|
|posttranscriptional regulation of gene expression|
|ubiquitin-dependent protein catabolic process|
|modification-dependent protein catabolic process|
|modification-dependent macromolecule catabolic process|
|immune response-activating signal transduction|
|negative regulation of cell cycle|
|myeloid leukocyte activation|
|proteolysis involved in cellular protein catabolic process|
|immune response-regulating signaling pathway|
|positive regulation of response to external stimulus|
|cellular protein catabolic process|
|leukocyte activation involved in immune response|
|cell activation involved in immune response|
|regulation of mitotic cell cycle|
|activation of immune response|
|cytokine-mediated signaling pathway|
|protein catabolic process|
|protein ubiquitination|
|regulated exocytosis|
|regulation of cell cycle process|
|regulation of defense response|
|leukocyte mediated immunity|
|protein modification by small protein conjugation|
|regulation of multi-organism process|
|exocytosis|
|regulation of cellular catabolic process|
|positive regulation of immune response|
|cellular macromolecule catabolic process|
|leukocyte activation|
|protein phosphorylation|
|protein modification by small protein conjugation or removal|
|regulation of catabolic process|
|secretion by cell|
|cellular response to cytokine stimulus|
|export from cell|
|macromolecule catabolic process|
|organonitrogen compound catabolic process|
|regulation of anatomical structure morphogenesis|
|cell activation|
|immune effector process|
|regulation of response to external stimulus|
|response to cytokine|
|cell-cell signaling|
|secretion|
|regulation of immune response|
|positive regulation of immune system process|
|response to abiotic stimulus|
|regulation of cell cycle|
|negative regulation of signal transduction|
|proteolysis|
|transmembrane transport|
|phosphorylation|
|negative regulation of cell communication|
|negative regulation of signaling|
|regulation of response to stress|
|negative regulation of response to stimulus|
|positive regulation of signal transduction|
|regulation of immune system process|
|intracellular signal transduction|
|cellular response to stress|
|organic substance catabolic process|
|cellular catabolic process|
|regulation of cell differentiation|
|positive regulation of cell communication|
|positive regulation of signaling|
|immune response|
|extracellular region|
|vesicle-mediated transport|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp25|Oligomycin-A 2μM R00 exp25]]|-2.97|
|[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|-2.79|
|[[:results:exp96|BI-2536 0.02μM R03 exp96]]|-2.71|
|[[:results:exp8|Brefeldin A 0.02μM R00 exp8]]|-2.67|
|[[:results:exp520|Rucaparib 6.5μM R08 exp520]]|-2.47|
|[[:results:exp79|Q15 2.7μM R02 exp79]]|-2.45|
|[[:results:exp497|Lead acetate 2000μM R08 exp497]]|-2.32|
|[[:results:exp457|Bisphenol F 50μM R08 exp457]]|-1.85|
|[[:results:exp19|Etoposide 1μM R00 exp19]]|-1.82|
|[[:results:exp126|GSK461364A 0.1μM R03 exp126]]|-1.76|
|[[:results:exp17|DABN 20μM R00 exp17]]|-1.73|
|[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|1.75|
|[[:results:exp170|Metformin 100 to 150μM on day4 R04 exp170]]|1.8|
|[[:results:exp406|Thalidomide 20μM R07 exp406]]|1.8|
|[[:results:exp42|BI-6727 0.001μM R01 exp42]]|1.85|
|[[:results:exp493|IL-3 9ng/ml R08 exp493]]|1.87|
|[[:results:exp183|IU1-C 25μM R04 exp183]]|1.89|
|[[:results:exp148|SB202190 10μM R03 exp148]]|1.9|
|[[:results:exp376|Losmapimod 1μM R07 exp376]]|1.91|
|[[:results:exp54|Taxol 0.002μM R01 exp54]]|1.96|
|[[:results:exp41|BI-2536 0.001μM R01 exp41]]|2.1|
|[[:results:exp496|Lead acetate 990μM R08 exp496]]|2.1|
|[[:results:exp58|UM131593 0.1μM R01 exp58]]|2.39|
|[[:results:exp274|Citral 50μM R06 exp274]]|2.43|
|[[:results:exp50|Nicotinamide 2000μM R01 exp50]]|2.48|
|[[:results:exp47|Lapatinib 5μM R01 exp47]]|2.76|
^Gene^Correlation^
|[[:human genes:h:hgc6.3|HGC6.3]]|0.504|
|[[:human genes:p:psmb1|PSMB1]]|0.412|
|[[:human genes:p:psmb2|PSMB2]]|0.411|
|[[:human genes:p:psmb8|PSMB8]]|0.401|
|[[:human genes:p:polr2j3|POLR2J3]]|0.4|
Global Fraction of Cell Lines Where Essential: 738/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|1/1|
|909776.0|1/1|
|bile duct|28/28|
|blood|28/28|
|bone|26/26|
|breast|33/33|
|central nervous system|56/56|
|cervix|4/4|
|colorectal|17/17|
|esophagus|13/13|
|fibroblast|1/1|
|gastric|16/16|
|kidney|21/21|
|liver|20/20|
|lung|74/75|
|lymphocyte|16/16|
|ovary|26/26|
|pancreas|24/24|
|peripheral nervous system|16/16|
|plasma cell|15/15|
|prostate|1/1|
|skin|24/24|
|soft tissue|9/9|
|thyroid|2/2|
|upper aerodigestive|22/22|
|urinary tract|29/29|
|uterus|5/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 1740
* **Expression level (log2 read counts)**: 6.4
{{:chemogenomics:nalm6 dist.png?nolink |}}